FibroGen Stock Craters After Roxadustat Setback, But There Is A Silver Lining |
| July 16, 2021 | July 2021 Bond Updates |
|
Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients. |
| View more at: https://www.forbes.com/sites/greatspeculations/2021/07/16/fibrogen-stock-craters-after-roxadustat-setback-but-there-is-a-silver-lining/ |
| Related News |
|